Compositions Comprising an HIV Protease Inhibitor such as VX 478 and a Water Soluble Vitamin E Compound such as Vitamin E-TPGS

摘要

PURPOSE: Pharmaceutical formulations containing HIV protease inhibitors, specifically including 3S-£3R*(1R*, 2S*)|-£3-££(4-aminophenyl)sulphonyl|(2-methylpropyl)-amino|-2-hydroxy-1-phenylmethyl)propylcarbamic acid tetrahyfro-3-furanyl ester(alternatively known as VX 478 or 141W94) and a tocopherol, by which bioavailability of HIV protease inhibitors is improved, and their use in medical therapy are provided. CONSTITUTION: The formulations for oral administration comprise (a) an HIV protease inhibitor and (b) water soluble tocopherol derivative such as Vitamine E-TPGS and (c) a hydrophilic non-aqueous solvent miscible with the (b) such as polyethylene glycol, propylene glycol or propylene pyrrolidone wherein the ratio of (a) to (b) is about 1:0.5-1:10 w/w.